Fulcrum Therapeutics Inc (FULC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Fulcrum Therapeutics Inc (FULC) has a cash flow conversion efficiency ratio of -0.072x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.19 Million) by net assets ($198.37 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Fulcrum Therapeutics Inc to measure how much of total assets are equity-financed.
Fulcrum Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Fulcrum Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Fulcrum Therapeutics Inc cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Fulcrum Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Fulcrum Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Accendra Health Inc
NYSE:ACH
|
-0.147x |
|
Gandhar Oil Refinery (India) Limited
NSE:GANDHAR
|
0.024x |
|
Ares Commercial Real Estate
NYSE:ACRE
|
-0.115x |
|
Tianyu Ecology & Landscape Co
SHG:603717
|
0.089x |
|
Blue Bird Tbk PT
JK:BIRD
|
0.040x |
|
Texas Ventures Acquisition III Corp
NASDAQ:TVA
|
-0.002x |
|
Hyundai Cement
KO:006390
|
0.059x |
|
Salmon Evolution Holding AS
OL:SALME
|
-0.013x |
Annual Cash Flow Conversion Efficiency for Fulcrum Therapeutics Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Fulcrum Therapeutics Inc from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see Fulcrum Therapeutics Inc (FULC) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $243.03 Million | $-2.22 Million | -0.009x | +97.64% |
| 2023-12-31 | $235.19 Million | $-90.97 Million | -0.387x | +20.72% |
| 2022-12-31 | $198.94 Million | $-97.05 Million | -0.488x | -31.50% |
| 2021-12-31 | $211.54 Million | $-78.48 Million | -0.371x | +34.19% |
| 2020-12-31 | $95.18 Million | $-53.66 Million | -0.564x | -24.43% |
| 2019-12-31 | $87.15 Million | $-39.48 Million | -0.453x | -52.60% |
| 2018-12-31 | $76.00 Million | $-22.56 Million | -0.297x | +98.04% |
| 2017-12-31 | $1.32 Million | $-20.07 Million | -15.185x | -- |
About Fulcrum Therapeutics Inc
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalasse… Read more